FF2039

FF2039 (compound 1J) inhibits purified HDAC1, HDAC2, HDAC4, and HDAC6 proteins, with IC₅₀ values of 1.03 μM, 2.15 μM, 12.4 μM, and 0.053 μM, respectively^[1].
FF2039 (10 μM; 24 h) reduces HDAC1 levels by 71% and induces significant degradation of HDAC6 in MM.1S cells. It binds HDAC6 and class I HDACs in MM.1S cells, inducing hyperacetylation of α-tubulin and histone H3. It also induces significant degradation of HDAC1 and HDAC6 in U-87MG cells, with degradation efficacy weaker than that observed in MM.1S cells^[1].
FF2039 (10 μM; 24 h) acts as a pan-HDAC degrader in MM.1S cells, achieving a maximum degradation rate of 90% for HDAC1 and 71%-76% for HDAC2, HDAC4 and HDAC6, with significant degradation effects observed as early as 6 h^[1].
FF2039 (72 h) inhibits the proliferation of MM.1S cells with an EC₅₀ of 2.8 μM; it also inhibits the proliferation of MDA-MB-231 and U-87MG cells, with an EC₅₀ of 28 μM for the former and 30 μM for the latter^[1].
FF2039 (10 μM; 48 h) induces cell cycle arrest and significant apoptosis in MM.1S cells, and significantly reduces the clonogenic capacity of MDA-MB-231 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.